Internal Pudental Artery Dysfunction in Diabetes Mellitus is Mediated by NOX1-Derived ROS-, Nrf2-, and Rho Kinase-Dependent Mechanisms

Hypertension

Volumn 68, Issue 4, 2016, Pages 1056-1064

  Alves Lopes, Rhéure ^a   Neves, Karla B ^a   Montezano, Augusto C ^b   Harvey, Adam ^b   Carneiro, Fernando S ^a   Touyz, Rhian M ^b   Tostes, Rita C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

diabetes mellitus; erectile dysfunction; NOX1; Nrf2; Rho associated kinases

Indexed keywords

3 NITROTYROSINE; GLUCOSE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; PEROXIREDOXIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; RHO KINASE; ROS PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ANTIOXIDANT; NFE2L2 PROTEIN, MOUSE; OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; INTERNAL PUDENDAL ARTERY DYSFUNCTION; LIGHT DARK CYCLE; MALE; MOUSE; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPLICATION; CYTOLOGY; DISEASE MODEL; ERECTILE DYSFUNCTION; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENETICS; IMMUNOBLOTTING; KNOCKOUT MOUSE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PENIS; PROCEDURES; RANDOMIZATION; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

ANIMALS; ANTIOXIDANTS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ERECTILE DYSFUNCTION; FEMALE; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NADH, NADPH OXIDOREDUCTASES; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; PENIS; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84981703929     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07518     Document Type: Article

References (57)

1. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813. doi: 10.1056/NEJM200006153422407.
2. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53:417-450.
3. Andersson KE, Stief CG. Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol. 1997;15:14-20.
4. Aboseif SR, Breza J, Orvis BR, Lue TF, Tanagho EA. Erectile response to acute and chronic occlusion of the internal pudendal and penile arteries. J Urol. 1989;141:398-402.
5. Yang G, Pan C, Lu J. Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. Int J Impot Res. 2010;22:310-317. doi: 10.1038/ijir.2010.21.
6. Vinik A, Richardson D. Erectile dysfunction in diabetes. Diabetes Rev. 1998;6:16-33.
7. Burnett AL. Erectile dysfunction. J Urol. 2006;175(3 pt 2):S25-S31. doi: 10.1016/S0022-5347(05)00309-5.
8. Michal V. Arterial disease as a cause of impotence. Clin Endocrinol Metab. 1982;11:725-748.
9. Touyz RM. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther. 2003;1:91-106. doi: 10.1586/14779072.1.1.91.
10. Zaki H, Nammas W, Shawky A, Mortada A, Zaki T. Prevalence of internal pudendal artery disease in diabetic patients with erectile dysfunction and angiographically documented multi-vessel coronary artery disease. The Egyp Heart J. 2013;65:87-91.
11. Herman A, Adar R, Rubinstein Z. Vascular lesions associated with impotence in diabetic and nondiabetic arterial occlusive disease. Diabetes. 1978;27:975-981.
12. Allahdadi KJ, Hannan JL, Ergul A, Tostes RC, Webb RC. Internal pudendal artery from type 2 diabetic female rats demonstrate elevated endothelin-1-mediated constriction. J Sex Med. 2011;8:2472-2483. doi: 10.1111/j.1743-6109.2011.02375.x.
13. Belin de Chantemèle EJ, Irfan Ali M, Mintz J, Stepp DW. Obesityinduced insulin resistance causes endothelial dysfunction without reducing the vascular response to hindlimb ischemia. Basic Res Cardiol. 2009;104:707-717.
14. Cheang WS, Wong WT, Tian XY, Yang Q, Lee HK, He GW, Yao X, Huang Y. Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice. Cardiovasc Res. 2011;92:267-275. doi: 10.1093/cvr/cvr233.
15. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058-1070. doi: 10.1161/CIRCRESAHA.110.223545.
16. Sedeek M, Nasrallah R, Touyz RM, Hébert RL. NADPH oxidases, reactive oxygen species, and the kidney: friend and foe. J Am Soc Nephrol. 2013;24:1512-1518. doi: 10.1681/ASN.2012111112.
17. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, Chandrasekar B. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol. 2012;303:H282-H296. doi: 10.1152/ajpheart.00231.2012.
18. Dikalova AE, Góngora MC, Harrison DG, Lambeth JD, Dikalov S, Griendling KK. Upregulation of Nox1 in vascular smooth muscle leads to impaired endothelium-dependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol. 2010;299:H673-H679. doi: 10.1152/ajpheart.00242.2010.
19. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis. 2011;216:321-326. doi: 10.1016/j.atherosclerosis.2011.02.028.
20. No JH, Kim YB, Song YS. Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev. 2014;19:111-117. doi: 10.15430/JCP.2014.19.2.111.
21. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002;99:11908-11913. doi: 10.1073/pnas.172398899.
22. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23:8137-8151.
23. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity? Clin Sci (Lond). 2014;127:111-122. doi: 10.1042/CS20130286.
24. Lopes RA, Neves KB, Pestana CR, Queiroz AL, Zanotto CZ, Chignalia AZ, Valim YM, Silveira LR, Curti C, Tostes RC. Testosterone induces apoptosis in vascular smooth muscle cells via extrinsic apoptotic pathway with mitochondria-generated reactive oxygen species involvement. Am J Physiol Heart Circ Physiol. 2014;306:H1485-H1494. doi: 10.1152/ajpheart.00809.2013.
25. Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013;127:1888-1902. doi: 10.1161/CIRCULATIONAHA.112.132159.
26. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond). 2013;124:191-202. doi: 10.1042/CS20120330.
27. De Young L, Yu D, Bateman RM, Brock GB. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl. 2004;25:830-836.
28. Hirata H, Kawamoto K, Kikuno N, Kawakami T, Kawakami K, Saini S, Yamamura S, Dahiya R. Restoring erectile function by antioxidant therapy in diabetic rats. J Urol. 2009;182:2518-2525. doi: 10.1016/j. juro.2009.07.009.
29. Zhang W, Wang Y, Yang Z, Qiu J, Ma J, Zhao Z, Bao T. Antioxidant treatment with quercetin ameliorates erectile dysfunction in streptozotocininduced diabetic rats. J Biosci Bioeng. 2011;112:215-218. doi: 10.1016/j. jbiosc.2011.05.013.
30. Harder B, Jiang T, Wu T, Tao S, Rojo de la Vega M, Tian W, Chapman E, Zhang DD. Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochem Soc Trans. 2015;43:680-686. doi: 10.1042/BST20150020.
31. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Redoxregulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem. 2004;279:31556-31567. doi: 10.1074/jbc. M403061200.
32. Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T, Wong PK, Chapman E, Fang D, Zhang DD. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 2014;28:708-722. doi: 10.1101/gad.238246.114.
33. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E, Zhang DD. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30:3275-3285. doi: 10.1128/MCB.00248-10.
34. Tretter L, Horvath G, Hölgyesi A, Essek F, Adam-Vizi V. Enhanced hydrogen peroxide generation accompanies the beneficial bioenergetic effects of methylene blue in isolated brain mitochondria. Free Radic Biol Med. 2014;77:317-330. doi: 10.1016/j.freeradbiomed.2014.09.024.
35. Wong PS, Roberts RE, Randall MD. Hyperoxic gassing with Tiron enhances bradykinin-induced endothelium-dependent and EDH-type relaxation through generation of hydrogen peroxide. Pharmacol Res. 2015;91:29-35. doi: 10.1016/j.phrs.2014.11.001.
36. Pernomian L, Gomes MS, Pernomian L, Moreira RP, Corrêa FM, de Oliveira AM. Vasoprotective effects of neurocompensatory response to balloon injury during diabetes involve the improvement of Mas signaling by TGF?1 activation. Vascul Pharmacol. 2015;64:36-48. doi: 10.1016/j. vph.2015.01.001.
37. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes. 2011;60:3055-3066. doi: 10.2337/db11-0807.
38. Velmurugan GV, Sundaresan NR, Gupta MP, White C. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res. 2013;100:143-150. doi: 10.1093/cvr/cvt125.
39. Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol. 2013;304:F808-F819. doi: 10.1152/ajprenal.00376.2012.
40. Vaziri ND, Liu S, Farzaneh SH, Nazertehrani S, Khazaeli M, Zhao YY. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease. Free Radic Biol Med. 2015;86:374-381. doi: 10.1016/j.freeradbiomed.2015.04.022.
41. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG; BEAM Study Investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327-336. doi: 10.1056/NEJMoa1105351.
42. de Zeeuw D, Akizawa T, Audhya P, et al; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492-2503. doi: 10.1056/NEJMoa1306033.
43. Zoja C, Benigni A, Remuzzi G. The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant. 2014;29(suppl 1):i19-i24. doi: 10.1093/ndt/gft224.
44. Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullinring ubiquitin ligases. Antioxid Redox Signal. 2010;13:1699-1712. doi: 10.1089/ars.2010.3211.
45. Lopes RA, Neves KB, Tostes RC, Montezano AC, Touyz RM. Downregulation of nuclear factor erythroid 2-related factor and associated antioxidant genes contributes to redox-sensitive vascular dysfunction in hypertension. Hypertension. 2015;66:1240-1250. doi: 10.1161/HYPERTENSIONAHA.115.06163.
46. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell. 2002;9:387-399.
47. Popov D. Vascular PTPs: current developments and challenges for exploitation in Type 2 diabetes-associated vascular dysfunction. Biochem Biophys Res Commun. 2009;389:1-4. doi: 10.1016/j.bbrc.2009.08.110.
48. Pandey NR, Benkirane K, Amiri F, Schiffrin EL. Effects of PPARgamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats. J Cardiovasc Pharmacol. 2007;49:346-354. doi: 10.1097/FJC.0b013e31804654d7.
49. Rajala RV, Wiskur B, Tanito M, Callegan M, Rajala A. Diabetes reduces autophosphorylation of retinal insulin receptor and increases protein-tyrosine phosphatase-1B activity. Invest Ophthalmol Vis Sci. 2009;50:1033-1040. doi: 10.1167/iovs.08-2851.
50. Suzuki YJ, Carini M, Butterfield DA. Protein carbonylation. Antioxid Redox Signal. 2010;12:323-325. doi: 10.1089/ars.2009.2887.
51. Day AM, Brown JD, Taylor SR, Rand JD, Morgan BA, Veal EA. Inactivation of a peroxiredoxin by hydrogen peroxide is critical for thioredoxin-mediated repair of oxidized proteins and cell survival. Mol Cell. 2012;45:398-408. doi: 10.1016/j.molcel.2011.11.027.
52. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta. 2010;1802:1276-1284. doi: 10.1016/j.bbadis.2010.05.002.
53. Ma Z, Zhang J, Ji E, Cao G, Li G, Chu L. Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats. Clin Exp Pharmacol Physiol. 2011;38:688-694. doi: 10.1111/j.1440-1681.2011.05561.x.
54. Gibson CL, Srivastava K, Sprigg N, Bath PM, Bayraktutan U. Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions. J Neurochem. 2014;129:816-826. doi: 10.1111/jnc.12681.
55. Toque HA, Nunes KP, Yao L, Liao JK, Webb RC, Caldwell RB, Caldwell RW. Activated Rho kinase mediates diabetes-induced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med. 2013;10:1502-1515. doi: 10.1111/jsm.12134.
56. Priviero FB, Toque HA, Nunes KP, Priolli DG, Teixeira CE, Webb RC. Impaired corpus cavernosum relaxation is accompanied by increased oxidative stress and up-regulation of the rho-kinase pathway in diabetic (Db/Db) Mice. PLoS One. 2016;11:e0156030. doi: 10.1371/journal. pone.0156030.
57. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, Mills TM. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7:119-122. doi: 10.1038/83258.